Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mara Campioni is active.

Publication


Featured researches published by Mara Campioni.


Science | 2008

Human CHN1 Mutations Hyperactivate α2-Chimaerin and Cause Duane's Retraction Syndrome

Noriko Miyake; John K. Chilton; Maria Psatha; Long Cheng; Caroline Andrews; Wai-Man Chan; Krystal Law; Moira Crosier; Susan Lindsay; Michelle C.M. Cheung; James P. Allen; Nick J. Gutowski; Sian Ellard; Elizabeth Young; Alessandro Iannaccone; Binoy Appukuttan; J. Timothy Stout; Stephen P. Christiansen; Maria Laura Ciccarelli; Alfonso Baldi; Mara Campioni; Juan Carlos Zenteno; Dominic Davenport; Laura E. Mariani; Mustafa Sahin; Sarah Guthrie; Elizabeth C. Engle

Duanes retraction syndrome (DRS) is a complex congenital eye movement disorder caused by aberrant innervation of the extraocular muscles by axons of brainstem motor neurons. Studying families with a variant form of the disorder (DURS2-DRS), we have identified causative heterozygous missense mutations in CHN1, a gene on chromosome 2q31 that encodes α2-chimaerin, a Rac guanosine triphosphatase–activating protein (RacGAP) signaling protein previously implicated in the pathfinding of corticospinal axons in mice. We found that these are gain-of-function mutations that increase α2-chimaerin RacGAP activity in vitro. Several of the mutations appeared to enhance α2-chimaerin translocation to the cell membrane or enhance its ability to self-associate. Expression of mutant α2-chimaerin constructs in chick embryos resulted in failure of oculomotor axons to innervate their target extraocular muscles. We conclude that α2-chimaerin has a critical developmental function in ocular motor axon pathfinding.


Science | 2008

Human CHN1 Mutations Hyperactivate α2-Chimaerin and Cause Duanes Retraction Syndrome

Noriko Miyake; John K. Chilton; Maria Psatha; Long Cheng; Caroline Andrews; Wai-Man Chan; Krystal Law; Moira Crosier; Susan Lindsay; Michelle C.M. Cheung; James P. Allen; Nick J. Gutowski; Sian Ellard; Elizabeth Young; Alessandro Iannaccone; Binoy Appukuttan; J. Timothy Stout; Stephen P. Christiansen; Maria Laura Ciccarelli; Alfonso Baldi; Mara Campioni; Juan Carlos Zenteno; Dominic Davenport; Laura E. Mariani; Mustafa Sahin; Sarah Guthrie; Elizabeth C. Engle

Duanes retraction syndrome (DRS) is a complex congenital eye movement disorder caused by aberrant innervation of the extraocular muscles by axons of brainstem motor neurons. Studying families with a variant form of the disorder (DURS2-DRS), we have identified causative heterozygous missense mutations in CHN1, a gene on chromosome 2q31 that encodes α2-chimaerin, a Rac guanosine triphosphatase–activating protein (RacGAP) signaling protein previously implicated in the pathfinding of corticospinal axons in mice. We found that these are gain-of-function mutations that increase α2-chimaerin RacGAP activity in vitro. Several of the mutations appeared to enhance α2-chimaerin translocation to the cell membrane or enhance its ability to self-associate. Expression of mutant α2-chimaerin constructs in chick embryos resulted in failure of oculomotor axons to innervate their target extraocular muscles. We conclude that α2-chimaerin has a critical developmental function in ocular motor axon pathfinding.


Current Cancer Drug Targets | 2009

HtrA Serine Proteases as Potential Therapeutic Targets in Cancer

Jeremy Chien; Mara Campioni; Viji Shridhar; Alfonso Baldi

The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.


Journal of Histochemistry and Cytochemistry | 2003

Distribution of the serine protease HtrA1 in normal human tissues.

Antonio De Luca; Maria De Falco; Anna Severino; Mara Campioni; Daniele Santini; Feliciano Baldi; Marco G. Paggi; Alfonso Baldi

The human HtrA family of proteases consists of three members: HtrA1, HtrA2, and HtrA3. In bacteria, the chief role of HtrA is recognition and degradation of misfolded proteins in the periplasm, combining a dual activity of chaperone and protease. In humans, the three HtrA homologues appear to be involved in diverse functions such as cell growth, apoptosis, allergic reactions, fertilization, control of blood pressure, and blood clotting. Previous studies using RNA blot hybridization have shown that the expression of HtrA1 is ubiquitous in normal human tissues. Here we show by immunohistochemistry (IHC) that HtrA1 is widely expressed, although different tissue distributions and/or levels of expression were detected in the different tissues examined. In particular, high to medium HtrA1 expression was detected in mature layers of epidermis, in secretory breast epithelium, in liver, and in kidney tubules of cortex, in concordance with its secretory properties. Furthermore, we show a higher protein expression level in the epithelium of proliferative endometrium, in contrast to epithelium of secretory endometrium, which is almost completely negative for this protein. This suggests a possible role for HtrA1 in the modulation of tissue activity in this organ. The various expression levels in human tissues indicate several possible roles for HtrA1 in different cell types.


Cell Death & Differentiation | 2008

HtrA1-dependent proteolysis of TGF- β controls both neuronal maturation and developmental survival

S. Launay; E. Maubert; N. Lebeurrier; Annette Tennstaedt; Mara Campioni; F. Docagne; C. Gabriel; L. Dauphinot; M. C. Potier; Michael Ehrmann; Alfonso Baldi; D. Vivien

Transforming growth factor-β (TGF-β) signalling controls a number of cerebral functions and dysfunctions including synaptogenesis, amyloid-β accumulation, apoptosis and excitotoxicity. Using cultured cortical neurons prepared from either wild type or transgenic mice overexpressing a TGF-β-responsive luciferase reporter gene (SBE-Luc), we demonstrated a progressive loss of TGF-β signalling during neuronal maturation and survival. Moreover, we showed that neurons exhibit increasing amounts of the serine protease HtrA1 (high temperature responsive antigen 1) and corresponding cleavage products during both in vitro neuronal maturation and brain development. In parallel of its ability to promote degradation of TGF-β1, we demonstrated that blockage of the proteolytic activity of HtrA1 leads to a restoration of TGF-β signalling, subsequent overexpression of the serpin type -1 plasminogen activator inhibitor (PAI-1) and neuronal death. Altogether, we propose that the balance between HtrA1 and TGF-β could be one of the critical events controlling both neuronal maturation and developmental survival.


Experimental Dermatology | 2005

Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance

Mara Campioni; Daniele Santini; Giuseppe Tonini; Raffaele Murace; Emanuele Dragonetti; Enrico P. Spugnini; Alfonso Baldi

Abstract:  Apoptosis protease‐activating factor‐1 (Apaf‐1) is a key regulator of the mitochondrial apoptotic pathway, being the central element of the multimeric apoptosome formed by procaspase 9, cytochrome c, and Apaf‐1 itself. In this review, the principal aspects about Apaf‐1 gene structure and function, and its role in the apoptotic machinery, are described. Moreover, the most recent findings about the involvement of this molecule in melanoma progression and chemoresistance, as well as the clinico‐pathological relevance of these findings in the treatment of this deadly disease, are reported.


Pharmacogenomics | 2008

The serine protease HtrA1 is a novel prognostic factor for human mesothelioma

Alfonso Baldi; Marcella Mottolese; Bruno Vincenzi; Mara Campioni; Pasquale Mellone; Mariapia Di Marino; Vincenzo Di Crescenzo; Paolo Visca; Simona Menegozzo; Enrico P. Spugnini; Gennaro Citro; Anna Ceribelli; Alessandra Mirri; Jeremy Chien; Viji Shridhar; Michael Ehrmann; Mario Santini; Francesco Facciolo

AIMS The objective of our study was to analyze the potential prognostic value of the expression of the serine protease HtrA1 and of EGFR in 70 malignant mesotheliomas. MATERIALS & METHODS Immunohistochemistry was used to determine the expression of HtrA1 and EGFR. Univariate and multivariate analyses were used to correlate expression of these molecular factors in combination with available clinicopathologic data to patient survival. RESULTS A positive, statistically significant relationship has been recorded between HtrA1 expression level and survival (p < 0.0001). By contrast, a negative relationship has been identified between EGFR expression and survival (p = 0.02). Moreover, extension of the tumor (T) and involvement of lymph nodes (N) advanced status (p = 0.001 and 0.002, respectively), as well as the sarcomatoid histotype (p = 0.005), correlated significantly with poor survival. Finally, by a multivariate Cox regression analysis, the only immunohistochemical parameter that resulted to influence overall survival was HtrA1 (p = 0.0001). Interestingly, the prognostic value of HtrA1 expression was completely independent from EGFR expression (p < 0.0001). CONCLUSION This is the first study of the relationship between HtrA1 expression and survival of mesothelioma patients. The data obtained strongly indicate the utilization of HtrA1 expression as a prognostic parameter for mesothelioma and suggest this serine protease as a possible molecular target for the treatment of malignant mesotheliomas.


Journal of Histochemistry and Cytochemistry | 2004

The Serine Protease HtrA1 Is Upregulated in the Human Placenta During Pregnancy

Antonio De Luca; Maria De Falco; Valentina Fedele; Luigi Cobellis; Annunziata Mastrogiacomo; Vincenza Laforgia; Ioana L. Tuduce; Mara Campioni; Domenico Giraldi; Marco G. Paggi; Alfonso Baldi

The placenta has a dynamic and continuous capacity for self-renewal. The molecular mechanisms responsible for controlling trophoblast proliferation are still unclear. It is generally accepted that the simultaneous activity of proteins involved in cell proliferation, apoptosis, and extracellular matrix degradation plays an important role in correct placental development. We investigated in depth the expression of the serine protease HtrA1 during pregnancy in human placenta by in situ hybridization and immunohistochemistry, we demonstrated that HtrA1 displayed a low level of expression in the first trimester of gestation and a strong increase of HtrA1 expression in the third trimester. Finally, by electron microscopy, we demonstrated that HtrA1 was localized either in the cytoplasm of placental cells, especially close to microvilli that characterized the plasma membrane of syncytiotrophoblast cells, or in the extracytoplasmic space of the stroma of placental villi, particularly in the spaces between collagen fibers and on collagen fibers themselves. The expression pattern of HtrA1 in human placentas strongly suggests a role for this protein in placental development and function. Moreover, on the basis of its subcellular distribution it can be postulated that HtrA1 acts on different targets, such as intracellular growth factors or extracellular matrix proteins, to favor the correct formation/function of the placenta. (J Histochem Cytochem 52:885–892, 2004)


Journal of Experimental & Clinical Cancer Research | 2008

Identification of genes down-regulated during lung cancer progression: A cDNA array study

Mara Campioni; Vincenzo Ambrogi; Eugenio Pompeo; Gennaro Citro; Mauro Castelli; Enrico P. Spugnini; Antonio Gatti; Pierluigi Cardelli; Laura Lorenzon; Alfonso Baldi; Tommaso Claudio Mineo

BackgroundLung cancer remains a major health challenge in the world. Survival for patients with stage I disease ranges between 40–70%. This suggests that a significant proportion of patients with stage I NSCLC may actually be under-staged.MethodsIn order to identify genes relevant for lung cancer development, we carried out cDNA array experiments employing 64 consecutive patients (58 men and 6 women) with a median age of 58 years and stage 1 or stage 2 non-small-cell lung cancer (NSCLC).ResultsBasic cDNA array data identified 14 genes as differentially regulated in the two groups. Quantitative RT-PCR analysis confirmed an effective different transcriptional regulation of 8 out of 14 genes analyzed. The products of these genes belong to different functional protein types, such as extra-cellular matrix proteins and proteases (Decorin and MMP11), genes involved in DNA repair (XRCC1), regulator of angiogenesis (VEGF), cell cycle regulators (Cyclin D1) and tumor-suppressor genes (Semaphorin 3B, WNT-5A and retinoblastoma-related Rb2/p130). Some previously described differences in expression patterns were confirmed by our array data. In addition, we identified and validated for the first time the reduced expression level of some genes during lung cancer progression.ConclusionComparative hybridization by means of cDNA arrays assisted in identifying a series of novel progression-associated changes in gene expression, confirming, at the same time, a number of previously described results.


Journal of Histochemistry and Cytochemistry | 2004

Pattern of Expression of HtrA1 During Mouse Development

Antonio De Luca; Maria De Falco; Luca De Luca; Roberta Penta; Viji Shridhar; Feliciano Baldi; Mara Campioni; Marco G. Paggi; Alfonso Baldi

The human HtrA family of proteases consists of four members: HtrA1, HtrA2, HtrA3, and HtrA4. In humans the four HtrA homologues appear to be involved in several important functions such as cell growth, apoptosis, and inflammatory reactions, and they control cell fate via regulated protein metabolism. In previous studies it was shown that the expression of HtrA1 was ubiquitous in normal adult human tissues. Here we examined the expression of HtrA1 protein and its corresponding mRNA during mouse embryogenesis using Northern blotting hybridization, RT-PCR, and immunohistochemical staining analyses. Our results indicate that HtrA1 is expressed in a variety of tissues in mouse embryos. Furthermore, this expression is regulated in a spatial and temporal manner. Relatively low levels of HtrA1 mRNA are detected in embryos at the beginning of organogenesis (E8), and the levels of expression increase during late organogenesis (E14-E19). Our results show that HtrA1 was expressed during embryonic development in specific areas where signaling by TGFβ family proteins plays important regulatory roles. The expression of HtrA1, documented both at mRNA and protein levels by RT-PCR and immunohistochemistry in the developing nervous system, is consistent with a possible role of this protein both in dividing and postmitotic neurons, possibly via its documented inhibitory effects on TGFβ proteins. An exhaustive knowledge of the different cell- and tissue-specific patterns of expression of HtrA1 in normal mouse embryos is essential for a critical evaluation of the exact role played by this protein during development.

Collaboration


Dive into the Mara Campioni's collaboration.

Top Co-Authors

Avatar

Alfonso Baldi

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Anna Severino

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Antonio De Luca

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Michael Ehrmann

University of Duisburg-Essen

View shared research outputs
Top Co-Authors

Avatar

Filippo Crea

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Gennaro Citro

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Bruno Vincenzi

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Feliciano Baldi

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Giovanna Liuzzo

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Luigi M. Biasucci

Catholic University of the Sacred Heart

View shared research outputs
Researchain Logo
Decentralizing Knowledge